Commercialization Challenges for Nucleic Acid Therapeutics: Toxicity, Manufacturing Costs, and Out-Licensing Attractiveness

A theme concerning barriers to the development and commercialization of nucleic acid therapeutics, including toxicity identified in late-stage clinical development, high costs of commercial production, and limited attractiveness for out-licensing to pharmaceutical companies.